Gilead licenses bi-specific tech from Danish biotech Genmab

The major biotech hopes to develop a bi-specific antibody targeting HIV using Genmab's DuoBody platform.

By Nicole Gray • Aug. 12, 2016

Allergan makes a buy, but not the one you think

Despite receiving an influx of over $33 billion in cash from the Teva deal, Allergan CEO Brent Saunders has indicated his preference for "stepping stone" deals. 

By Lisa LaMotta • Aug. 11, 2016

Medivation bullish on Xtandi as PDUFA approaches

CEO David Hung stayed mum on contract negotiations with potential suitors during the recent quarterly call. 

By Nicole Gray • Aug. 11, 2016

AstraZeneca bolsters stake in Moderna by $140 million

As a result of the new equity investment, AstraZeneca now owns a 9% share in the messenger RNA company.

By Nicole Gray • Aug. 11, 2016

Biogen's hemophilia spinoff has a shiny new name

Bioverativ, named after its Biogen roots and the word 'veracity', is set to debut on public markets during the first half of 2017. 

By Lisa LaMotta • Aug. 10, 2016

Swiss Helsinn picks up late-stage cancer drug from MEI Pharma

Known for its supportive care products, Helsinn hopes to expand into drug development. 

By Nicole Gray • Aug. 9, 2016

Sanofi, Boehringer bank on strength through consolidation

The two companies have been given the OK to move forward with their asset swap, provided they sell off some assets. 

By Lisa LaMotta • Aug. 5, 2016

Teva bolsters generics consolidation with purchase of Allergan's distributor

Teva will pay Allergan $500 million for Anda Inc., the fourth largest wholesale distributor of generics in the U.S.

By Edwin Lopez • Aug. 4, 2016

Inovio going it alone after Roche departure

The biotech vows to continue development of its hepatitis B drug after Roche bowed out of the partnership. 

By Lisa LaMotta • Aug. 3, 2016

Takeover rumors juice Biogen stock, but fade fast

According to a report, Merck and Allergan have informally approached Biogen about a potential sale, spurring a stock jump of 9% Tuesday.

By Ned Pagliarulo • Aug. 3, 2016

Pfizer addresses speculation about divorce

The pharma giant is not showing its cards regarding a potential split of the company, but instead talked strategy and taxes during its Q2 call.

By Lisa LaMotta • Aug. 2, 2016

Amgen secures rights to cancer immunotherapy from biotech Advaxis

Advaxis believes its technology will allow for more personalized treatment of cancer than existing drugs.

By Ned Pagliarulo • Aug. 2, 2016

Pfizer buys Bamboo for $150 million, bets on gene therapy

The deal, potentially worth $645 million if all milestones are met, gives Pfizer full ownership of the company, its pipeline, and a dedicated manufacturing facility in North Carolina.

By Edwin Lopez • Aug. 1, 2016

Private equity firm Advent buys 50% stake in InVentiv

InVentiv, a major pharmaceutical contract company, said it would no longer pursue an IPO as a result of Advent's equity investment. 

By Nicole Gray • Aug. 1, 2016

GSK, Verily launch $715 million bet on bioelectronic medicines

The newly created company aims to develop tiny, implantable devices to treat chronic diseases by modifying electrical signals in the body.

By Ned Pagliarulo • Aug. 1, 2016

Bayer leans on partnering for new growth

BioPharma Dive spoke with Bayer’s Head of Innovation about why partnerships are vital for staying competitive and expanding into new areas. 

By Nicole Gray • July 31, 2016

Editas teams up with Italian gene therapy institute

The two aim to develop stem cell-based and T-cell therapies for rare diseases through a three-year collaboration. 

By Nicole Gray • July 29, 2016

US, UK pledge to combat antibiotic resistance through new alliance

Called Carb-X, the partnership brings together governmental, academic and industry-based experts to address "super bacteria" before resistance becomes unmanageable.

By Nicole Gray • July 29, 2016

Pfizer may sell its stake in Latin America's largest manufacturer

A Reuters report suggests Teva and Mylan are some of the companies interested in buying Pfizer's 40% stake in a Brazilian joint venture.

By Nicole Gray • July 28, 2016

GSK enters $230 million licensing deal with Janssen

GlaxoSmithKline saw an opportunity to develop a new asthma treatment using the IL-33 pathway.

By Nicole Gray • July 28, 2016

US regulators clear Teva, Allergan generics deal

But the Israeli drugmaker will have to sell off nearly 80 drugs in order to clear antitrust concerns raised by the Federal Trade Commission. 

By Ned Pagliarulo • July 27, 2016

Janssen: Bristol-Myers' newest Opdivo combo research partner

A number of companies have recently looked to team up with Bristol-Myers as its checkpoint inhibitor Opdivo continues to rack up approvals. 

By Nicole Gray • July 27, 2016

Kite eyes off-the-shelf T-cell therapies with UCLA research deal

A leader in the race to develop an autologous CAR-T therapy, Kite appears to be hedging its bets with the new agreement. 

By Nicole Gray • July 26, 2016

Swiss group Galencia buys US biotech Relypsa for $1.5 billion

Relypsa's recently approved kidney drug became morere valuable after AstraZeneca saw its competing treatment snubbed by the FDA. 

By Ned Pagliarulo • July 21, 2016

Mylan gets 'all clear' from EU regulators for $7.2 billion Meda deal

Together, the two generics companies would have a foothold in many emerging markets.

By Nicole Gray • July 21, 2016